Gilead Sciences | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Agios Pharmaceuticals USD 1.66B 128.6M 2024-12
ALKERMES USD 2.06B 99.72M 2024-12
Alnylam Pharmaceuticals USD 4.24B 34.94M 2024-12
Amgen USD 91.84B 956M 2024-12
Biogen USD 28.05B 263.9M 2024-12
BioMarin Pharmaceutical USD 6.99B 137.74M 2024-12
Bristol-Myers Squibb USD 92.6B 1.07B 2024-12
Eli Lilly USD 78.71B 3.11B 2024-12
Gilead Sciences USD 59B 4.47B 2024-12
GlaxoSmithKline GBP 59.46B 1.41B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Incyte USD 5.44B 431.89M 2024-12
J&J USD 180.1B 1.82B 2024-12
Merck USD 117.11B 426M 2024-12
Moderna USD 14.14B 1.66B 2024-12
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 213.4B 6.08B 2024-12
PTC Therapeutics USD 1.71B 137.21M 2024-12
Regeneron Pharmaceuticals USD 37.76B 317.5M 2024-12
Sanofi 129.76B 3.29B 2024-06
Sarepta Therapeutics USD 3.96B 363.24M 2024-12
United Therapeutics USD 7.36B 240.9M 2024-12
Vertex Pharmaceuticals USD 22.53B 293M 2024-12



Gilead Sciences Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.